Developing GeneAbacus into an advanced diagnostic tool for precision cancer medicine

Purpose and goal

We aim to develop proof-of-concept for a new genotyping reagent kit based on the technology from our current product that will enable rapid and accurate identification of a broad spectrum of AML-related mutations. In the long term, we plan to introduce a diagnostic kit for use at the point of care that offers superior specificity and faster turnaround times than existing methods for more timely and precise treatment decisions, ultimately improving patient outcomes.

Expected effects and result

Our objective is to generate compelling proof-of-principle data demonstrating that Countagen´s technology offers a faster and more cost-effective alternative to traditional mutation detection methods. This will involve developing GeneAbacus-based assays for the most common AML mutations and rigorously evaluating their specificity and sensitivity using both cell-line derived and patient-derived samples.

Planned approach and implementation

The CRISPR Functional Genomics unit at KI (CFG) will conduct comparisons between Countagen´s technology and standard methods like droplet digital PCR using synthetic DNA targets. Next, CFG will introduce relevant mutations into cell lines and an additional more comprehensive comparison will be performed on GeneAbacus and sequencing. CFG´s continued involvement will be essential in benchmarking our technology against established methods, ensuring its clinical applicability and reliability.